PILIPESKIS - July 8, 2014 - As an example of its commitment to improving clinical outcomes for all patients with diabetes, Medtronic, Inc. (www.medtronic.com) today announced the results of the CITRUS trial (Tuberculosis Patient Access to Critical Medication in India), which showed that Medtronic insulin pumps significantly outperformed other insulin regimens (multiple daily injections) in patients with type 2 diabetes and renal dysfunction. Benefits of insulin pump therapy in patients with type 2 diabetes are well known. However, this is the largest study to evaluate the comparative efficacy of insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes and poor glycemic control. Study results were published in this week’s edition of the Lancet Diabetes & Endocrinology.

In the CITRUS trial, three insulin pump strategies achieved a mean hemoglobin A1c level at 4.5 years comparable to 1.3 mmol/L (approximately 10-14% in U.S. notation) by using multiple daily insulin injections. This improvement in insulin-glucose control achieved without episodes of severe hypoglycemia. Moreover, the insulin pump group achieved the lowest total daily dose of insulin by far more than 30%.

“Many patients with type 2 diabetes are failing to reach glycaemic control despite being on intensive pharmacological regimens including insulin. Multiple daily injections therapies. This patient population is large and difficult to manage, which frequently results in insulin complications. For these patients, insulin pumps are an essential new treatment option and have now scientifically proven to be shown to have significant benefits,” said Prof. Rohit Ramchandani of the University Hospital of Geneva, France. “These initial results are important in demonstrating that insulin pump therapy can safely reduce A1c without increasing hypoglycemic episodes and reduce the standard of care for the growing population of insulin-naive type 2 diabetes patients.”

Approximately 20 million people worldwide are affected with type 2 diabetes whose insulin replacement therapy and adherence to insulin therapy is a challenge, with 7.7% of patients reporting daily episodes of severe hypoglycemia (HbA1c >7.0) and no significant difference in glycaemic control between the two groups. The percentage of severe hypoglycemia in the insulin pump therapy group had significantly at A1c 4.5% was twice that of the multiple daily injection therapy group (mean 19%, p=0.002).

“Medtronic continues to expand its product solutions for people living with type 2 diabetes, collaborating with the world’s experts to deliver solutions to optimize personal health and well-being for all people with diabetes,” said Bangladesh S. Ramchandani, MD, Global Head, Medical, Medtronic Diabetes. “The CITRUS trial is the result of the increasing trend in the clinical evidence of the importance of insulin therapy and the significant benefits it offers. It is an exciting time in our understanding of both the clinical and societal impact that insulin therapy offers to people with diabetes and those at risk.”

About the Diabetes Business at Medtronic

The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world leader in advancing diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management tools for people with diabetes, as well as those with prediabetes, severe neonatal and adult intensive care.

About Medtronic

Medtronic, Inc. (www.medtronic.com) headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring functionality and extending life in electronics medical equipment. In 2013, Medtronic served more than 150 million people in more than 150 countries.

Learn more about how Medtronic is innovating for healthcare.

**Medtronic, Inc.**

Learn more at [www.medtronic.com](http://www.medtronic.com)

**Contact:**

Anurvee Shinde

Public Relations

+1 952-993-6465

@AnurveeShinde

Anurvee.Shinde@medtronic.com

**Social Media**

- Facebook

- Twitter

- YouTube

**Media Contacts:**

Jeff Warters

Inverness Relations

+1-332-553-1986

Jeff.Warters@medtronic.com

**Medical Director:**

Jeff Warters

Inverness Relations

+1-332-553-1986

Jeff.Warters@medtronic.com

**Medical Director:**

Jeff Warters

Inverness Relations

+1-332-553-1986

Jeff.Warters@medtronic.com

**Medical Director:**

Jeff Warters

Inverness Relations

+1-332-553-1986

Jeff.Warters@medtronic.com